Cargando…

HIV-1 drug resistance in recently HIV-infected pregnant mother’s naïve to antiretroviral therapy in Dodoma urban, Tanzania

BACKGROUND: HIV resistance affects virological response to therapy and efficacy of prophylaxis in mother-to-child-transmission. The study aims to assess the prevalence of HIV primary resistance in pregnant women naïve to antiretrovirals. METHODS: Cross sectional baseline analysis of a cohort of HIV...

Descripción completa

Detalles Bibliográficos
Autores principales: Vairo, Francesco, Nicastri, Emanuele, Liuzzi, Giuseppina, Chaula, Zainab, Nguhuni, Boniface, Bevilacqua, Nazario, Forbici, Federica, Amendola, Alessandra, Fabeni, Lavinia, De Nardo, Pasquale, Perno, Carlo Federico, Cannas, Angela, Sakhoo, Calistus, Capobianchi, Maria Rosaria, Ippolito, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3849050/
https://www.ncbi.nlm.nih.gov/pubmed/24053581
http://dx.doi.org/10.1186/1471-2334-13-439
_version_ 1782293868758171648
author Vairo, Francesco
Nicastri, Emanuele
Liuzzi, Giuseppina
Chaula, Zainab
Nguhuni, Boniface
Bevilacqua, Nazario
Forbici, Federica
Amendola, Alessandra
Fabeni, Lavinia
De Nardo, Pasquale
Perno, Carlo Federico
Cannas, Angela
Sakhoo, Calistus
Capobianchi, Maria Rosaria
Ippolito, Giuseppe
author_facet Vairo, Francesco
Nicastri, Emanuele
Liuzzi, Giuseppina
Chaula, Zainab
Nguhuni, Boniface
Bevilacqua, Nazario
Forbici, Federica
Amendola, Alessandra
Fabeni, Lavinia
De Nardo, Pasquale
Perno, Carlo Federico
Cannas, Angela
Sakhoo, Calistus
Capobianchi, Maria Rosaria
Ippolito, Giuseppe
author_sort Vairo, Francesco
collection PubMed
description BACKGROUND: HIV resistance affects virological response to therapy and efficacy of prophylaxis in mother-to-child-transmission. The study aims to assess the prevalence of HIV primary resistance in pregnant women naïve to antiretrovirals. METHODS: Cross sectional baseline analysis of a cohort of HIV + pregnant women (HPW) enrolled in the study entitled Antiretroviral Management of Antenatal and Natal HIV Infection (AMANI, peace in Kiswahili language). The AMANI study began in May 2010 in Dodoma, Tanzania. In this observational cohort, antiretroviral treatment was provided to all women from the 28(th) week of gestation until the end of the breastfeeding period. Baseline CD4 cell count, viral load and HIV drug-resistance genotype were collected. RESULTS: Drug-resistance analysis was performed on 97 naïve infected-mothers. The prevalence of all primary drug resistance and primary non-nucleoside reverse-transcriptase inhibitors resistance was 11.9% and 7.5%, respectively. K103S was found in two women with no M184V detection. HIV-1 subtype A was the most commonly identified, with a high prevalence of subtype A1, followed by C, D, C/D recombinant, A/C recombinant and A/D recombinant. HIV drug- resistance mutations were detected in A1 and C subtypes. CONCLUSION: Our study reports an 11.9% prevalence rate of primary drug resistance in naïve HIV-infected pregnant women from a remote area of Tanzania. Considering that the non-nucleoside reverse-transcriptase inhibitors are part of the first-line antiretroviral regimen in Tanzania and all of Africa, resistance surveys should be prioritized in settings where antiretroviral therapy programs are scaled up.
format Online
Article
Text
id pubmed-3849050
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-38490502013-12-04 HIV-1 drug resistance in recently HIV-infected pregnant mother’s naïve to antiretroviral therapy in Dodoma urban, Tanzania Vairo, Francesco Nicastri, Emanuele Liuzzi, Giuseppina Chaula, Zainab Nguhuni, Boniface Bevilacqua, Nazario Forbici, Federica Amendola, Alessandra Fabeni, Lavinia De Nardo, Pasquale Perno, Carlo Federico Cannas, Angela Sakhoo, Calistus Capobianchi, Maria Rosaria Ippolito, Giuseppe BMC Infect Dis Research Article BACKGROUND: HIV resistance affects virological response to therapy and efficacy of prophylaxis in mother-to-child-transmission. The study aims to assess the prevalence of HIV primary resistance in pregnant women naïve to antiretrovirals. METHODS: Cross sectional baseline analysis of a cohort of HIV + pregnant women (HPW) enrolled in the study entitled Antiretroviral Management of Antenatal and Natal HIV Infection (AMANI, peace in Kiswahili language). The AMANI study began in May 2010 in Dodoma, Tanzania. In this observational cohort, antiretroviral treatment was provided to all women from the 28(th) week of gestation until the end of the breastfeeding period. Baseline CD4 cell count, viral load and HIV drug-resistance genotype were collected. RESULTS: Drug-resistance analysis was performed on 97 naïve infected-mothers. The prevalence of all primary drug resistance and primary non-nucleoside reverse-transcriptase inhibitors resistance was 11.9% and 7.5%, respectively. K103S was found in two women with no M184V detection. HIV-1 subtype A was the most commonly identified, with a high prevalence of subtype A1, followed by C, D, C/D recombinant, A/C recombinant and A/D recombinant. HIV drug- resistance mutations were detected in A1 and C subtypes. CONCLUSION: Our study reports an 11.9% prevalence rate of primary drug resistance in naïve HIV-infected pregnant women from a remote area of Tanzania. Considering that the non-nucleoside reverse-transcriptase inhibitors are part of the first-line antiretroviral regimen in Tanzania and all of Africa, resistance surveys should be prioritized in settings where antiretroviral therapy programs are scaled up. BioMed Central 2013-09-21 /pmc/articles/PMC3849050/ /pubmed/24053581 http://dx.doi.org/10.1186/1471-2334-13-439 Text en Copyright © 2013 Vairo et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Vairo, Francesco
Nicastri, Emanuele
Liuzzi, Giuseppina
Chaula, Zainab
Nguhuni, Boniface
Bevilacqua, Nazario
Forbici, Federica
Amendola, Alessandra
Fabeni, Lavinia
De Nardo, Pasquale
Perno, Carlo Federico
Cannas, Angela
Sakhoo, Calistus
Capobianchi, Maria Rosaria
Ippolito, Giuseppe
HIV-1 drug resistance in recently HIV-infected pregnant mother’s naïve to antiretroviral therapy in Dodoma urban, Tanzania
title HIV-1 drug resistance in recently HIV-infected pregnant mother’s naïve to antiretroviral therapy in Dodoma urban, Tanzania
title_full HIV-1 drug resistance in recently HIV-infected pregnant mother’s naïve to antiretroviral therapy in Dodoma urban, Tanzania
title_fullStr HIV-1 drug resistance in recently HIV-infected pregnant mother’s naïve to antiretroviral therapy in Dodoma urban, Tanzania
title_full_unstemmed HIV-1 drug resistance in recently HIV-infected pregnant mother’s naïve to antiretroviral therapy in Dodoma urban, Tanzania
title_short HIV-1 drug resistance in recently HIV-infected pregnant mother’s naïve to antiretroviral therapy in Dodoma urban, Tanzania
title_sort hiv-1 drug resistance in recently hiv-infected pregnant mother’s naïve to antiretroviral therapy in dodoma urban, tanzania
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3849050/
https://www.ncbi.nlm.nih.gov/pubmed/24053581
http://dx.doi.org/10.1186/1471-2334-13-439
work_keys_str_mv AT vairofrancesco hiv1drugresistanceinrecentlyhivinfectedpregnantmothersnaivetoantiretroviraltherapyindodomaurbantanzania
AT nicastriemanuele hiv1drugresistanceinrecentlyhivinfectedpregnantmothersnaivetoantiretroviraltherapyindodomaurbantanzania
AT liuzzigiuseppina hiv1drugresistanceinrecentlyhivinfectedpregnantmothersnaivetoantiretroviraltherapyindodomaurbantanzania
AT chaulazainab hiv1drugresistanceinrecentlyhivinfectedpregnantmothersnaivetoantiretroviraltherapyindodomaurbantanzania
AT nguhuniboniface hiv1drugresistanceinrecentlyhivinfectedpregnantmothersnaivetoantiretroviraltherapyindodomaurbantanzania
AT bevilacquanazario hiv1drugresistanceinrecentlyhivinfectedpregnantmothersnaivetoantiretroviraltherapyindodomaurbantanzania
AT forbicifederica hiv1drugresistanceinrecentlyhivinfectedpregnantmothersnaivetoantiretroviraltherapyindodomaurbantanzania
AT amendolaalessandra hiv1drugresistanceinrecentlyhivinfectedpregnantmothersnaivetoantiretroviraltherapyindodomaurbantanzania
AT fabenilavinia hiv1drugresistanceinrecentlyhivinfectedpregnantmothersnaivetoantiretroviraltherapyindodomaurbantanzania
AT denardopasquale hiv1drugresistanceinrecentlyhivinfectedpregnantmothersnaivetoantiretroviraltherapyindodomaurbantanzania
AT pernocarlofederico hiv1drugresistanceinrecentlyhivinfectedpregnantmothersnaivetoantiretroviraltherapyindodomaurbantanzania
AT cannasangela hiv1drugresistanceinrecentlyhivinfectedpregnantmothersnaivetoantiretroviraltherapyindodomaurbantanzania
AT sakhoocalistus hiv1drugresistanceinrecentlyhivinfectedpregnantmothersnaivetoantiretroviraltherapyindodomaurbantanzania
AT capobianchimariarosaria hiv1drugresistanceinrecentlyhivinfectedpregnantmothersnaivetoantiretroviraltherapyindodomaurbantanzania
AT ippolitogiuseppe hiv1drugresistanceinrecentlyhivinfectedpregnantmothersnaivetoantiretroviraltherapyindodomaurbantanzania